Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI). NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemi...

Full description

Bibliographic Details
Main Authors: Egle Stukaite-Ruibiene, Rimvydas Norvilas, Vaidas Dirse, Sigita Stankeviciene, Goda Elizabeta Vaitkeviciene
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Pathology and Oncology Research
Subjects:
case report
targeted therapy
tyrosine kinase inhibitors
acute lymphoblastic leukemia
imatinib
BCR-ABL1-like
Online Access:https://www.por-journal.com/articles/10.3389/pore.2022.1610570/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2022.1610570/full

Similar Items